Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
Future Oncol
; 13(2): 175-184, 2017 Jan.
Article
em En
| MEDLINE
| ID: mdl-27640448
ABSTRACT
Basal cell carcinomas are the most common form of skin cancer. Some develop into advanced cases not suitable for standard therapy. Vismodegib is the first-in-class oral hedgehog pathway inhibitor (which is dysregulated in 90% of basal cell carcinomas), and has demonstrated efficacy for advanced disease in clinical trials. An UK expert panel met to discuss management strategies for adverse events associated with vismodegib (most commonly taste disturbances, muscle cramps and alopecia). Managing patient expectations and implementing treatment breaks were considered important strategies. Quinine was useful to alleviate muscle cramps. For taste disturbances, food swaps alongside dietician referral were suggested. The experts concluded that these common adverse events can be successfully managed to allow optimum treatment duration of vismodegib.
Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Neoplasias Cutâneas
/
Carcinoma Basocelular
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Anilidas
/
Antineoplásicos
Tipo de estudo:
Guideline
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Reino Unido